Silence Therapeutics PLC

SLN

Company Profile

  • Business description

    Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

  • Contact

    72 Hammersmith Road
    LondonW14 8TH
    GBR

    T: +44 2034576900

    E: [email protected]

    https://www.silence-therapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    116

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,841.908.300.09%
CAC 407,696.2758.28-0.75%
DAX 4023,787.45146.68-0.61%
Dow JONES (US)44,828.53344.110.77%
FTSE 1008,822.910.29-0.00%
HKSE23,916.06153.88-0.64%
NASDAQ20,601.10207.971.02%
Nikkei 22539,810.8824.980.06%
NZX 50 Index12,766.6062.120.49%
S&P 5006,279.3551.930.83%
S&P/ASX 2008,603.007.200.08%
SSE Composite Index3,472.3211.170.32%

Market Movers